Brynn E. Marks, MD, MSHPEd
Assistant Professor of Pediatrics (Endocrinology and Diabetes) at the Children's Hospital of Philadelphia
Attending Physician, Division of Endocrinology & Diabetes, Children's Hospital of Philadelphia
Director of Technology, Diabetes Center, Children's Hospital of Philadelphia
Department: Pediatrics
Contact information
Children's Hospital of Philadelphia
Division of Endocrinology and Diabetes
The Hub for Clinical Collaboration
3501 Civic Center Boulevard
7th Floor, Office 7547
Philadelphia, PA 19104
Division of Endocrinology and Diabetes
The Hub for Clinical Collaboration
3501 Civic Center Boulevard
7th Floor, Office 7547
Philadelphia, PA 19104
Office: 267-426-4925
Publications
Education:
BA (Psychology)
Georgetown University, 2007.
MD
Thomas Jefferson University Sidney Kimmel Medical College, 2011.
MSHPEd
Massachusetts General Hospital Institute of Health Professions, 2019.
Permanent linkBA (Psychology)
Georgetown University, 2007.
MD
Thomas Jefferson University Sidney Kimmel Medical College, 2011.
MSHPEd
Massachusetts General Hospital Institute of Health Professions, 2019.
Description of Clinical Expertise
type 1 diabetes, cystic fibrosis-related diabetes, post-transplant diabetesDescription of Research Expertise
type 1 diabetes, cystic fibrosis-related diabetes, diabetes technology, automated insulin delivery, continuous glucose monitor, insulin pump, medical education, healthcare inequitiesSelected Publications
Wolf R, Patel D, Gera S, Molano G, DOliveira T, Meighan S, Brown E, Marks BE: Does the OP5 Automated Insulin Delivery System Close the Gap in Glycemic Control between White and Black Youth with Type 1 Diabetes? Diabetes Technology & Therapeutics June 2025.Meighan S, Johnson D, Gallop RJ, Kelly A, Putman MS, Marks BE: Alternative approaches to glucose measurement during oral glucose tolerance testing in youth with cystic fibrosis. American Diabetes Association 85th Scientific Sessions, Chicago, Illinois June 2025.
Gera S, Iyer J, Meighan S, March CA, Marks BE: A Review of Real-World Evidence About the Use of Automated Insulin Delivery Systems in People with Type 1 Diabetes. Endocr Pract June 2025.
Iyer J, Meighan S, Marks BE: Pediatric Endocrinology Trainees’ Education and Knowledge about Automated Insulin Delivery Systems. American Diabetes Association 85th Scientific Sessions, Chicago, Illinois June 2025.
Scully KJ, Reed M, Douvas J, Putman MS, Marks BE: The Effect of Omnipod 5 Automated Insulin Delivery on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes. Diabetes Technology & Therapeutics May 2025.
Meighan S, Lipman T, VanGraafeiland B, Marks BE: Continuous Glucose Monitoring Attrition in Youth with Type 1 Diabetes. Sci Diabetes Self Manag Care Feb 2025.
Gera S, Rearson A, Baker G, Douvas J, Alicea Trelles N, Gallop R, Meighan S, Marks BE: Changes in 90-day Time in Range among Youth with Type 1 Diabetes Initiating Different Automated Insulin Delivery Systems. J Clin Endocrinol Metab Jan 2025.
Lahoti A, Haque R, Bianco ME, Choudhary A, Clark AL, Marks BE, Pinnaro CT, Shah AS, Stefater-Richards M, Thaker VV, Wolf RM, Tryggestad JB: Trends of Diabetes in Youth (TrenDY) during COVID-19 across the United States. Journal of Clinical Endocrinology & Metabolism 2025.
Gera S, Rearson A, Gallop RJ, Marks BE: Minimum Continuous Glucose Monitor Data Required to Assess Glycemic Control in Youth with Type 1 Diabetes. Diabetes Technology & Therapeutics 2025.
Chu P, Parimi N, Wolf RM, Brown EA, Kelly A, Marks BE: Real-World Safety and Effectiveness of U200 Insulin Use in Automated Insulin Delivery Systems in Adolescents and Young Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2025.